The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines Immunogenicity

The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines Immunogenicity

COVID-19-specific vaccines are efficient prophylactic weapons against SARS-CoV-2 virus. However, boosting innate responses may represent an innovative way to immediately fight future emerging viral infections or boost vaccines. MV130 is a mucosal immunotherapy, based on a mixture of whole heat-inact...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Carlos del Fresno, Juan García-Arriaza, Sarai Martínez-Cano, Ignacio Heras-Murillo, Aitor Jarit-Cabanillas, Joaquín Amores-Iniesta, Paola Brandi, Gillian Dunphy, Carmen Suay-Corredera, Maria Rosaria Pricolo, Natalia Vicente, Andrés López-Perrote, Sofía Cabezudo, Ana González-Corpas, Oscar Llorca, Jorge Alegre-Cebollada, Urtzi Garaigorta, Pablo Gastaminza, Mariano Esteban, David Sancho
Formato: article
Lenguaje:EN
Publicado: Frontiers Media S.A. 2021
Materias:
innate immunity
viral infections
polybacterial mucosal immunotherapy
SARS-CoV-2
vaccine immunogenicity
Immunologic diseases. Allergy
RC581-607
Acceso en línea:https://doaj.org/article/af5d6f5a1ddb4342b33ea0dcb74a03d1
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/af5d6f5a1ddb4342b33ea0dcb74a03d1

Ejemplares similares